Nanalysis Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Nanalysis Scientific şirketinin toplam hissedar öz sermayesi CA$24.2M ve toplam borcu CA$14.7M olup, bu da borç-öz sermaye oranını 61% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$51.5M ve CA$27.3M dir.

Anahtar bilgiler

61.0%

Borç/özkaynak oranı

CA$14.75m

Borç

Faiz karşılama oranı	n/a
Nakit	CA$1.13m
Eşitlik	CA$24.17m
Toplam yükümlülükler	CA$27.29m
Toplam varlıklar	CA$51.45m

Son finansal sağlık güncellemeleri

Recent updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Oct 28

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

Jun 19

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 12

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Mar 24

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Feb 08

We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt

Jan 31

Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?

Aug 26

Nanalysis Scientific Corp.'s (CVE:NSCI) Price Is Right But Growth Is Lacking

Apr 17

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Dec 08

Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?

Jul 15

Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?

Jan 24

Is Nanalysis Scientific (CVE:NSCI) Using Debt Sensibly?

Mar 29

Nanalysis Scientific (CVE:NSCI) Has Debt But No Earnings; Should You Worry?

Dec 14

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NSCI 'nin kısa vadeli varlıkları ( CA$17.7M ) kısa vadeli yükümlülüklerini ( CA$12.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: NSCI şirketinin kısa vadeli varlıkları ( CA$17.7M ) uzun vadeli yükümlülüklerini ( CA$14.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NSCI 'nin net borç/öz sermaye oranı ( 56.4% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: NSCI şirketinin borç/öz sermaye oranı son 5 yılda 7.6% seviyesinden 61% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: NSCI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: NSCI un, serbest nakit akışı her yıl % 37.8 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Nanalysis Scientific Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt

Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?

Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?

Recent updates

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Second quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.039 loss in 2Q 2023)

Nanalysis Scientific Corp. to Report Q2, 2024 Results on Aug 28, 2024

High number of new and inexperienced directors

Nanalysis Scientific Corp.'s (CVE:NSCI) CEO Will Probably Find It Hard To See A Huge Raise This Year

First quarter 2024 earnings released: CA$0.02 loss per share (vs CA$0.042 loss in 1Q 2023)

Nanalysis Scientific Corp. to Report Q1, 2024 Results on May 29, 2024

Nanalysis Scientific Corp. (CVE:NSCI) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Full year 2023 earnings released: CA$0.16 loss per share (vs CA$0.098 loss in FY 2022)

Nanalysis Scientific Corp., Annual General Meeting, Jun 26, 2024

Nanalysis Scientific Corp. to Report Q4, 2023 Results on Apr 25, 2024

Nanalysis Scientific Corp. Announces Resignation of Kham Lin as A Director

Nanalysis Corp. Receives Funding Supporting AI Software Development for Detection of Illicit Substances

Benign Growth For Nanalysis Scientific Corp. (CVE:NSCI) Underpins Stock's 25% Plummet

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 5 million.

Nanalysis Scientific Corp. announced that it expects to receive CAD 1 million in funding

Nanalysis Scientific Corp. (CVE:NSCI) Shares Fly 43% But Investors Aren't Buying For Growth

Nanalysis Scientific Corp. Provides Earnings Guidance for the Fourth Quarter 2023

We Think Nanalysis Scientific (CVE:NSCI) Has A Fair Chunk Of Debt

Third quarter 2023 earnings released: CA$0.06 loss per share (vs CA$0.026 loss in 3Q 2022)

Nanalysis Scientific Corp. to Report Q3, 2023 Results on Nov 29, 2023

Would Nanalysis Scientific (CVE:NSCI) Be Better Off With Less Debt?

Second quarter 2023 earnings released: CA$0.04 loss per share (vs CA$0.024 loss in 2Q 2022)

Nanalysis Scientific Corp. to Report Q2, 2023 Results on Aug 24, 2023

Nanalysis Scientific Corp. to Report Q1, 2023 Results on May 25, 2023

Nanalysis Scientific Corp. announced that it has received CAD 4.1287 million in funding

Full year 2022 earnings released: CA$0.10 loss per share (vs CA$0.025 loss in FY 2021)

Nanalysis Scientific Corp.'s (CVE:NSCI) Price Is Right But Growth Is Lacking

Is Nanalysis Scientific (CVE:NSCI) Using Too Much Debt?

Third quarter 2022 earnings released

Nanalysis Scientific Corp. to Report Q3, 2022 Results on Nov 29, 2022

Price target decreased to CA$2.75

High number of new and inexperienced directors

Nanalysis Scientific Corp. Provides Revenue Guidance for the Third Quarter Ended September 30, 2022

Price target decreased to CA$2.75

Nanalysis Scientific Corp. to Report Q2, 2022 Results on Aug 25, 2022

Nanalysis Scientific Corp. Announces Executive Changes

Is Nanalysis Scientific (CVE:NSCI) Weighed On By Its Debt Load?

Nanalysis Scientific Corp. Announces Appointment of Kham Lin as New Director

First quarter 2022 earnings released: CA$0.017 loss per share (vs CA$0.007 loss in 1Q 2021)

Nanalysis Scientific Corp. to Report Q1, 2022 Results on May 31, 2022

Full year 2021 earnings released: CA$0.03 loss per share (vs CA$0.056 loss in FY 2020)

High number of new and inexperienced directors

Nanalysis Scientific Corp. to Report Fiscal Year 2021 Results on Apr 28, 2022

Nanalysis Scientific Corp. has completed a Follow-on Equity Offering in the amount of CAD 10.725 million.

Health Check: How Prudently Does Nanalysis Scientific (CVE:NSCI) Use Debt?

Nanalysis Scientific Corp. (TSXV:NSCI) completed the acquisition of K'(Prime) Technologies Inc.

Nanalysis Scientific Corp. announced that it expects to receive CAD 0.2025 million in funding

High number of new and inexperienced directors

Third quarter 2021 earnings released: CA$0.01 loss per share (vs CA$0.017 loss in 3Q 2020)

Second quarter 2021 earnings released

Nanalysis Scientific Corp. has completed a Composite Units Offering in the amount of CAD 8.00004 million.

Nanalysis Scientific Corp. announced that it has received CAD 1.797638 million in funding

First quarter 2021 earnings released: CA$0.007 loss per share (vs CA$0.014 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.056 loss per share (vs CA$0.03 loss in FY 2019)

Is Nanalysis Scientific (CVE:NSCI) Using Debt Sensibly?

Nanalysis Scientific Corp. Signs Strategic OEM Partnership for Magnetic Resonance Electronics Sales

New 90-day high: CA$0.50

Nanalysis Scientific (CVE:NSCI) Has Debt But No Earnings; Should You Worry?

Third quarter 2020 earnings released: CA$0.017 loss per share

New 90-day low: CA$0.40

New 90-day low - CA$0.45

Earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin